Ibrutinib, IMBRUVICA 140 mg film-coated tablets, Ibrutinib, Prednison acis 5 mg, Tabletten, Prednison acis 20 mg, Tabletten, Ibrutinib, Prednison acis 50 mg, Tabletten
PCYC-1146-IM
Phase 2 small_molecule active
Quick answer
Ibrutinib, IMBRUVICA 140 mg film-coated tablets, Ibrutinib, Prednison acis 5 mg, Tabletten, Prednison acis 20 mg, Tabletten, Ibrutinib, Prednison acis 50 mg, Tabletten for Chronic Graft Versus Host Disease (cGVHD) is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Chronic Graft Versus Host Disease (cGVHD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active